S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 74, Issue 9, 2015, Pages 1748-1755

  Tomcik, Michal ^a,b   Palumbo Zerr, Katrin ^a   Zerr, Pawel ^a   Avouac, Jerome ^c   Dees, Clara ^a   Sumova, Barbora ^a,b   Distler, Alfiya ^a   Beyer, Christian ^a   Andres Cerezo, Lucie ^b   Becvar, Radim ^b   Distler, Oliver ^d   Grigorian, Mariam ^e   Schett, Georg ^a   Senolt, Ladislav ^b   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALVASCULIN; COLLAGEN; HYDROXYPROLINE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; PROTEIN S 100; S100A4 PROTEIN, HUMAN; S100A4 PROTEIN, MOUSE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; EXPERIMENTAL FIBROSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; FEMALE; FIBROBLAST; KNOCKOUT MOUSE; MALE; METABOLISM; MIDDLE AGED; SKIN; YOUNG ADULT;

ADULT; AGED; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; S100 PROTEINS; SCLERODERMA, SYSTEMIC; SKIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 84942110141     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204516     Document Type: Article

References (50)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
3. Ebralidze A, Tulchinsky E, Grigorian M, et al. Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+-binding protein family. Genes Dev 1989;3:1086-93.
4. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33:637-68.
5. Klingelhofer J, Senolt L, Baslund B, et al. Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: putative involvement in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2007;56:779-89.
6. Ambartsumian N, Klingelhofer J, Grigorian M, et al. The metastasis-associated Mts1 (S100A4) protein could act as an angiogenic factor. Oncogene 2001;20:4685-95.
7. Schneider M, Kostin S, Strom CC, et al. S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytes. Cardiovasc Res 2007;75:40-50.
8. Helfman DM, Kim EJ, Lukanidin E, et al. The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 2005;92:1955-8.
9. Senolt L, Grigorian M, Lukanidin E, et al. S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases. Ann Rheum Dis 2006;65:1645-8.
10. Cerezo LA, Kuncova K, Mann H, et al. The metastasis promoting protein S100A4 is increased in idiopathic inflammatory myopathies. Rheumatology (Oxford) 2011;50:1766-72.
11. Oslejskova L, Grigorian M, Gay S, et al. The metastasis associated protein S100A4: a potential novel link to inflammation and consequent aggressive behaviour of rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis 2008;67:1499-504.
12. Bergmann C, Akhmetshina A, Dees C, et al. Inhibition of glycogen synthase kinase 3beta induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis 2011;70:2191-8.
13. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
14. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
15. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clinical and experimental rheumatology 2003;21:S39-41.
16. Zibert JR, Skov L, Thyssen JP, et al. Significance of the S100A4 protein in psoriasis. J Invest Dermatol 2010;130:150-60.
17. Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun 2012;3:735.
18. Dees C, Tomcik M, Palumbo-Zerr K, et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor beta in systemic sclerosis. Arthritis Rheum 2012;64:3006-15.
19. Chen R, Huang C, Morinelli TA, et al. Blockade of the effects of TGF-beta1 on mesangial cells by overexpression of Smad7. J Am Soc Nephrol 2002;13:887-93.
20. Horn A, Palumbo K, Cordazzo C, et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum 2012;64:2724-33.
21. Palumbo K, Zerr P, Tomcik M, et al. The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011;70:1320-6.
22. Kramer M, Dees C, Huang J, et al. Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 2013;72:614-20.
23. Lin NY, Beyer C, Giessl A, et al. Autophagy regulates TNFalpha-mediated joint destruction in experimental arthritis. Ann Rheum Dis 2013;72:761-8.
24. Dees C, Schlottmann I, Funke R, et al. The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis 2014;73:1232-9.
25. Tomcik M, Zerr P, Pitkowski J, et al. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-beta signalling to prevent fibrosis. Ann Rheum Dis 2013.
26. Khodzhigorova A, Distler A, Lang V, et al. Inhibition of sumoylation prevents experimental fibrosis. Ann Rheum Dis 2012;71:1904-8.
27. Distler A, Deloch L, Huang J, et al. Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. Ann Rheum Dis 2013;72:1575-80.
28. EL Naaman C, Grum-Schwensen B, Mansouri A, et al. Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene. Oncogene 2004;23:3670-80.
29. Reich N, Tomcik M, Zerr P, et al. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis 2012;71:737-45.
30. Weingartner S, Zerr P, Tomcik M, et al. Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Ann Rheum Dis 2012;71:1895-9.
31. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011;208:961-72.
32. Horn A, Kireva T, Palumbo-Zerr K, et al. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis 2012;71:785-9.
33. Beyer C, Reich N, Schindler SC, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012;71:1019-26.
34. Beyer C, Schramm A, Akhmetshina A, et al. beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 2012;71:761-7.
35. Dees C, Zerr P, Tomcik M, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum 2011;63:1396-404.
36. Palumbo-Zerr K, Horn A, Distler A, et al. Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1. Ann Rheum Dis 2012;71:2051-4.
37. Zerr P, Distler A, Palumbo-Zerr K, et al. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. Am J Pathol 2012;181:1672-80.
38. Zerr P, Palumbo-Zerr K, Distler A, et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood 2012;120:2909-17.
39. Beyer C, Schett G, Distler O, et al. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010;62:2831-44.
40. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974;54:880-9.
41. Xie R, Schlumbrecht MP, Shipley GL, et al. S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling. Lab Invest 2009;89:937-47.
42. Kawakita T, Espana EM, Higa K, et al. Activation of Smad-mediated TGF-beta signaling triggers epithelial-mesenchymal transitions in murine cloned corneal progenitor cells. J Cell Physiol 2013;228:225-34.
43. Beyer C, Schett G, Gay S, et al. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther 2009;11:220.
44. Distler JH, Jungel A, Pileckyte M, et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 2007;56:4203-15.
45. Copple BL. Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-beta-dependent mechanisms. Liver Int 2010;30:669-82.
46. Matsuura I, Lai CY, Chiang KN. Functional interaction between Smad3 and S100A4 (metastatin-1) for TGF-beta-mediated cancer cell invasiveness. Biochem J 2010;426:327-35.
47. Yamamoto T, Takagawa S, Katayama I, et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112:456-62.
48. Lawson WE, Polosukhin VV, Zoia O, et al. Characterization of fibroblast-specific protein 1 in pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:899-907.
49. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007;13:952-61.
50. Sack U, Walther W, Scudiero D, et al. S100A4-induced cell motility and metastasis is restricted by the Wnt/beta-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell 2011;22:3344-54.